Tenet Healthcare (THC) Earnings Date & Reports

Key Takeaways

• Tenet Healthcare reported third-quarter 2026 net operating revenues of $5.63 billion, up 6.5% year over year and above analyst consensus estimates.
• Adjusted diluted earnings per share (EPS) rose 79.5% to $6.64, well ahead of Wall Street expectations of roughly $4.60 to $4.68 per share.
• Net income available to common shareholders reached $1.00 billion, or $12.41 per diluted share on a generally accepted accounting principles (GAAP) basis.
• Management raised its full-year 2026 outlook, lifting adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance to $5.05 billion to $5.20 billion.
• The hospital segment grew same-hospital adjusted admissions by 3.2%, while the ambulatory segment (USPI) increased adjusted EBITDA by 9.1%.
• The company generated $1.1 billion of adjusted free cash flow in the quarter and repurchased $255 million of shares.
• For more context, explore Tenet Healthcare's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Interested in automated market insights? Explore Trending AI Robots to discover AI-driven trading strategies.

Earnings Context and Why It Matters

Tenet Healthcare is one of the largest diversified healthcare services companies in the United States, operating hospitals and a fast-growing ambulatory surgery center business through United Surgical Partners International (USPI). Its quarterly results serve as a key barometer of hospital volumes, payer mix, and the broader demand for higher-acuity care. Heading into the report, investors were focused on whether the company could sustain its multi-quarter streak of earnings beats and translate strong operations into higher free cash flow. The third-quarter release carried extra weight because Tenet had already raised its outlook after the second quarter, setting a high bar for execution. Management's decision to raise guidance again signals continued momentum in patient demand and disciplined cost control.

Reported Results

Tenet Healthcare reported third-quarter 2026 net operating revenues of $5.631 billion, up 6.5% from $5.289 billion in the prior-year period and above consensus estimates near $5.5 billion. Adjusted diluted EPS came in at $6.64, a 79.5% increase from $3.70 a year earlier and far above analyst expectations of roughly $4.60 to $4.68. On a GAAP basis, net income available to common shareholders was $1.00 billion, or $12.41 per diluted share, compared with $342 million, or $3.86 per diluted share, in the third quarter of 2025.

Consolidated adjusted EBITDA totaled $1.355 billion. The hospital segment generated $818 million of adjusted EBITDA, up from $607 million a year earlier, driven by 3.2% same-hospital adjusted admissions growth and strong expense management. The ambulatory segment delivered $537 million of adjusted EBITDA, a 9.1% increase, with same-facility system-wide revenues up 4.5% and net revenue per case up 6.1%.

Alongside the results, Tenet raised its full-year 2026 guidance. The company now expects net operating revenues of $22.05 billion to $22.45 billion, adjusted EBITDA of $5.05 billion to $5.20 billion, and adjusted diluted EPS of $22.05 to $23.01.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, breakout candidates, and emerging market opportunities, the screener helps investors identify actionable setups far more efficiently than manual research. Explore the AI Screener to see how data-driven screening can complement your own earnings and market analysis.

Market Reaction and Investor Sentiment

Tenet's third-quarter results represented another quarter of meaningful outperformance, with adjusted EPS coming in more than 40% above consensus. The report reinforced confidence in the company's high-acuity hospital strategy and its growing ambulatory business, which continues to expand margins and free cash flow. Investor sentiment had already been constructive entering the print, with the stock outperforming the broader market in the weeks prior. The raised full-year guidance—particularly the $195 million midpoint increase in adjusted EBITDA expectations—was a key positive signal. At the same time, management acknowledged headwinds from reduced exchange (Affordable Care Act marketplace) admissions and the eventual non-recurrence of Conifer transition-related benefits, which investors will weigh against the strong underlying operational performance.

Forward Outlook and Key Factors to Monitor

Tenet entered 2026 with strong growth expectations and has now raised its guidance twice, with management noting that more than 40% of this year's total guidance increase stems from fundamental outperformance rather than one-time items. Looking ahead, the company expects its diversified business mix to support continued adjusted EBITDA growth in 2027, even after excluding transition-related contributions.

Several factors will shape the outlook. First, investors should monitor same-hospital admission trends and revenue per adjusted admission, which management says are being pressured by a decline in exchange volumes but supported by commercial employer pricing. Second, the ambulatory segment remains a growth engine, with USPI continuing to invest in new centers and acquisitions; over $100 million was deployed in the third quarter alone.

Cost and margin discipline will also matter, as Tenet has credited sustained expense efficiencies for its margin expansion. Finally, capital allocation remains a focal point, with the company prioritizing share repurchases, debt reduction, and ambulatory growth. Management's early 2027 commentary will take shape in the fourth-quarter update, making that report the next key catalyst for investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations